Invariant p53 immunostaining in primary and recurrent breast cancer

In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following chemotherapy. The aim of this study was to test the hypothesis that breast cancer recurrences following adjuvant therapy exhibit aberrant p53 expressio...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2004-01, Vol.40 (1), p.28-32
Main Authors: Poelman, S.M., Heimann, R., Fleming, G.F., Recant, W.M., Conzen, S.D.
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Adult
Aged
Biological and medical sciences
Breast cancer
Breast Neoplasms - metabolism
Cyclin-Dependent Kinase Inhibitor p21
Cyclins - metabolism
Female
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry - methods
Mammary gland diseases
Medical sciences
Metastasis
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local - metabolism
p21
p53
Pharmacology. Drug treatments
Recurrence
Tumor Suppressor Protein p53 - metabolism
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following chemotherapy. The aim of this study was to test the hypothesis that breast cancer recurrences following adjuvant therapy exhibit aberrant p53 expression. We therefore evaluated p53 expression in paired primary and recurrent breast tumours: 48% of primary and 32% of recurrent tumours had abnormally increased p53 expression. Of the paired samples, 84% showed no change in p53 expression between the primary tumour and the metastasis. In fact, in no case was low (normal) p53 expression in the primary tumour followed by the development of high (aberrant) p53 expression in the recurrence. These results show that increased p53 expression is not selected for in the malignant cells emerging following adjuvant therapy, suggesting that p53 expression is unlikely to play a central role in breast cancer recurrences.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(03)00661-0